Angelini Pharma
Angelini Pharma, a prominent player in the global pharmaceutical industry, is headquartered in Rome, Italy, with significant operations across Europe, North America, and Asia. Founded in 1919, the company has established itself as a leader in the development of innovative healthcare solutions, particularly in the areas of pain management, mental health, and consumer health products. With a diverse portfolio that includes prescription medications and over-the-counter products, Angelini Pharma is recognised for its commitment to quality and efficacy. The company’s unique approach combines scientific research with a deep understanding of patient needs, positioning it as a trusted partner in healthcare. Notable achievements include strategic partnerships and a strong market presence, underscoring its role as a key contributor to advancements in the pharmaceutical sector.
DitchCarbon Score
How does Angelini Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Angelini Pharma's score of 21 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Angelini Pharma's reported carbon emissions
In 2023, Angelini Pharma reported total carbon emissions of approximately 16.8 million tonnes CO2e, with Scope 1 emissions accounting for about 16.8 million tonnes CO2e and Scope 2 emissions at around 4.7 million tonnes CO2e. This represents an increase from 2022, where the company emitted about 15 million tonnes CO2e in Scope 1 and approximately 9.4 million tonnes CO2e in Scope 2. The breakdown of Scope 1 emissions in 2023 includes approximately 1.5 million tonnes CO2e from mobile combustion, 164,000 tonnes CO2e from fugitive emissions, and about 15 million tonnes CO2e from stationary combustion. For Scope 2 emissions, the total was around 4.7 million tonnes CO2e, with a market-based approach accounting for about 6.2 million tonnes CO2e. Currently, Angelini Pharma has not set specific reduction targets or initiatives as part of their climate commitments. The absence of documented reduction targets suggests a need for further development in their sustainability strategy. As the pharmaceutical industry increasingly focuses on reducing carbon footprints, Angelini Pharma's ongoing emissions data highlights the importance of establishing clear climate goals to align with global sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project2022 | 2023 | |
|---|---|---|
| Scope 1 | 15,036,800 | 00,000,000 |
| Scope 2 | 7,677,500 | 0,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Angelini Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
